最新ニュース Grifols (NASDAQ:GRFS) 株価情報

Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols, S.A. - American Depositary Shares

Grifols SA

News

Contracts

GRFS

Grifols Held An Extraordinary Meeting This Afternoon, During Which The Content Of A Letter Sent By Brookfield Capital Partners To The Transaction Committee Of The Board Of Directors Was Reviewed, Saying Under The Current Circumstances, Brookfield Is Not In A Position To Proceed With A Potential Offer For Grifols; Board Agrees That It Is Not Feasible For The Transaction To Move Forward

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">third-quarter results</a>.
Dell Technologies reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $2.05. Quarterly revenue came in at $24.37 billion, which missed the consensus estimate of $24.65 billion and is an increase over revenue of $22.25 billion from the same period last year.
Dell reported better-than-expected earnings for its third quarter, while sales missed estimates.
Dell shares tumbled 13.1% to $123.24 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares tumbled 89.2% to $11.65 in pre-market trading after surging 919% on Tuesday.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 17.7% to $7.18 in pre-market trading.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell 15% to $2.90 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance below estimates</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) fell 12.7% to $15.13 in pre-market trading after the company reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) shares dipped 10.1% to $242.95 in pre-market trading after the company revised its FY25 subscription revenue guidance.</li>
<li>Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) shares declined 9.2% to $16.40 in pre-market trading following third-quarter earnings.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) dipped 8.7% to $35.69 in pre-market trading. HP reported in-line earnings for its fourth quarter, while sales topped estimates. HP said it expects first-quarter adjusted earnings of between 70 cents and 76 cents per share, versus the 85 cent estimate, and fiscal 2025 earnings of between $3.45 and $3.75 per share, versus the $3.60 estimate.</li>
<li>Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) shares declined 8.2% to $292.06 in pre-market trading following third-quarter earnings.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares declined 7.7% to $4.67 in pre-market trading after announcing a $25 million registered direct offering.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares dipped 5.5% to $344.37 in pre-market trading. CrowdStrike posted upbeat results for its third quarter. The company said it expects fourth-quarter revenue to be between $1.029 billion and $1.035 billion versus estimates of $1.03 billion. The company anticipates fourth-quarter adjusted earnings of 84 cents to 86 cents per share versus estimates of 86 cents per share.</li>
<li>TriMas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRS#NYSE">TRS</a>) declined 4.2% to $25.31 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADSK

CRWD

DELL

PGHL

POET

WDAY

Dell, HP, CrowdStrike, 3D Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/NTNX/news">better-than-expected first-quarter financial results.</a>
Nutanix reported quarterly earnings of 42 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $590.96 million which beat the analyst consensus estimate of $571.78 million.
Nutanix shares jumped 8.8% to $78.71 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 82.1% to $1.12 in pre-market trading.</li>
<li>Cyclerion Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) rose 72.8% to $2.35 in pre-market trading.</li>
<li>Infobird Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) gained 56% to $2.87 in pre-market trading after declining around 6% on Tuesday.</li>
<li>T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) gained 39.7% to $0.51 in pre-market trading after jumping around 103% on Tuesday.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) climbed 24.8% to $21.50 in pre-market trading after dipping more than 20% on Tuesday.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) gained 24.3% to $85.00 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Creative Media &amp; Community Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) gained 15% to $0.2767 in pre-market trading.</li>
<li>Creative Global Technology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) gained 13.6% to $4.44 in pre-market trading. Creative Global Technology priced its IPO at $4 per share.   </li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 10.9% to $2.44 in pre-market trading after dipping 20% on Tuesday. The company announced a registered direct offering of 50 million shares at $2 per unit.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares tumbled 89.2% to $11.65 in pre-market trading after surging 919% on Tuesday.</li>
<li>CIMG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMG#NASDAQ">IMG</a>) shares fell 24.4% to $1.21 in pre-market trading after jumping 154% on Tuesday.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 17.7% to $7.18 in pre-market trading.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) fell 15.6% to $0.3120 in pre-market trading. Blue Star Foods shares jumped 55% on Tuesday after the company announced a $1.5 million buyback program.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell 15% to $2.90 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) declined 14.2% to $3.56 in pre-market trading after surging 24% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell 13.1% to $123.24 in today's pre-market trading. Dell reported better-than-expected earnings for its third quarter, while sales missed estimates.</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) fell 12.7% to $15.13 in pre-market trading after the company reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) shares dipped 10.1% to $242.95 in pre-market trading after the company revised its FY25 subscription revenue guidance.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) dipped 8.7% to $35.69 in pre-market trading. HP reported in-line earnings for its fourth quarter, while sales topped estimates. HP said it expects first-quarter adjusted earnings of between 70 cents and 76 cents per share, versus the 85 cent estimate, and fiscal 2025 earnings of between $3.45 and $3.75 per share, versus the $3.60 estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

AMBA

BSFC

CGTL

CMCT

CTXR

CYCN

IDAI

IFBD

NTNX

QMCO

RGTI

Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ALKS

ALMS

APLM

CTKB

FRES

GCTK

HCWB

INCY

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<a href="https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brookfield-offer">https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brookfield-offer</a>
&nbsp;
<a href="https://www.bloomberg.com/quote/GRF:SM">Grifols SA</a>'s board of directors said it won't recommend that shareholders accept <a href="https://www.bloomberg.com/quote/BN:CN">Brookfield Asset Management's</a> indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).
The offer "significantly undervalues the company's fundamental prospects and its long-term potential," Grifols said in a <a href="https://www.bloomberg.com/news/terminal/SN7M90MB2SJT">regulatory filing</a> on Tuesday. The asset manager's disclosure was a tentative, non-binding indication requested by the Spanish regulator following media reports.

Management

'Grifols Board Issues Unfavorable Opinion On Brookfield Offer; Brookfield And Grifols Family Have Been In Talks Since July; Investors Are Prepared To Push Back Against Low-Ball Offer' - Bloomberg News

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Tuesday.
Shares of AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ACM/earnings">fourth-quarter results</a>.
The company reported better-than-expected earnings for its fourth quarter. The company&#8217;s quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion.
Aecom shares declined 3.3% to $105.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Hanmi Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) shares tumbled 20.9% to $20.24 in pre-market trading.</li>
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) fell 20.7% to $16.96 in pre-market trading.</li>
<li>Flushing Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) declined 12.2% to $15.25 in pre-market trading.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 10.3% to $68.98 in today's pre-market trading after the company issued an update on early Phase MRGPRX2 and MRGPRX4 programs.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined 9.1% to $8.38 in pre-market trading.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) shares fell 7.3% to $8.37 in pre-market trading after jumping over 20% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 5.8% to $30.86 in pre-market trading after jumping around 17% on Monday.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares fell 5.8% to $1.61 in pre-market trading. Globalstar announced its board of directors authorized a reverse stock split of its common stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

FFIC

GRDN

GSAT

HAFC

NEXN

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Brookfield Capital Partners Confirmed Request for Due Diligence Information; Considers €10.50/Share for Grifols Class A Shares; €7.62/Share for Class B Shares

Grifols To Hold Extraordinary Meeting Tuesday To Consider €10.50/Share For Grifols Class A Shares From Brookfield Capital Partners

WIIM

Grifols shares are trading higher following a report suggesting banks are preparing to submit final offers for a buyout debt deal.

<a href="https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols">https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols</a>
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 billion) to back the take-private of Spanish pharmaceutical producer Grifols SA.

Reported Earlier, 'Banks To Pitch Roughly €11 Billion Buyout Debt For Grifols; Lenders Expected To Submit Best And Final Offers Next Week; Takeover Deal Likely To Rank Among Biggest In Europe This Year' - Bloomberg News

Mason Capital Criticizes Grifols Board For Governance Failures And Shareholder Value Loss; Calls For Independent Directors And Improved Oversight; Claims Brookfield Transaction Undervalues Grifols

Grifols shares are trading higher following a report suggesting Brookfield is seeking information on the company's related-party deals and that it is confident it can line up financing

Financing

Brookfield Is Said To Seek Info On Grifols Related-Party Deals; Said To Be Confident It Can Line Up Financing

Grifols shares are trading higher after the company announced it received FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution.

<ul>
<li>Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis</li>
<li>Grifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients &nbsp;</li>
</ul>
BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:<a href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding has received approval from the United States Food and Drug Administration (FDA) for pediatric patients.
The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer complications.
Grifols FS biosurgery treatment is commercialized as VISTASEAL&#x2122; in the U.S. and Canada, and VERASEAL&#x2122; in Europe and elsewhere. Both brands are marketed and distributed by Johnson &amp; Johnson MedTech, as part of a strategic collaboration between the two companies announced in 2019.
Grifols FS combines two plasma proteins, fibrinogen and thrombin, and is applied with Johnson &amp; Johnson MedTech's airless spray technology to rapidly form clots. The FS solution is now available in 18 countries.

Biotech

General

Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution

Success Could Lead To FDA Approval For One Of The First Treatments For Chemical Warfare Ocular Damage, Phase 2 Trial For Dry Eye Disease Planned For 2025

Grifols Partners With BARDA For Testing Ocular Immunoglobulin Eye Drops As Treatment For Sulfur Mustard-Induced Eye Injury

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs &nbsp;
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LYus6vr6e9kkAq1UFdnEMG_rFiPgb3buMnD1EXp_OmcSohXze17gw6aPoLbrltGSuEs4Oj_YBED1OsQ6UqvuXoA04Rxz2r_79ReiInhcuExlX32QTGd56a2BjByK0lEV2Auzdzx-M99lVVQrUqndKj7GNY6lCKL-oJM-GlHGcFWg5kTjkN3KgKGyDst1XAKO">GigaGen Inc.</a>, a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of <a href="https://www.globenewswire.com/Tracker?data=xsHSTMVkJs06-0kEN0wfCEXi2BXZZz3aZPpT4p5W8XMG2hSTSIHgnvK74MzZpn-TkPKjm6mxkYHbFBWQt1hzfA==">Grifols</a>, announced today that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The award, valued at up to $135.2 million, is to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time.

GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Tuesday.
Shares of Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) fell in today's pre-market trading after the company announced a <a href="https://www.benzinga.com/news/24/09/40991747/snowflake-stock-dips-on-offering-after-hours-what-to-know">$2 billion private placement of senior convertible notes.</a>
Snowflake announced it intends to offer $1 billion aggregate principal amount of its convertible senior notes due 2027 and a $1 billion aggregate principal amount of its convertible senior notes due 2029.
Snowflake shares fell 3.3% to $109.56 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) shares tumbled 17.1% to $93.43 in pre-market trading after the company received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W&#8217;s Dragon Train game..</li>
<li>Hawaiian Electric Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HE#NASDAQ">HE</a>) shares fell 10.5% to $9.75 in pre-market trading. Hawaiian Electric Industries raised $500 million via secondary stock offering of 54 million shares at $9.25 per share.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) fell 5.8% to $2.34 in pre-market trading. Uxin shares jumped 54% on Monday after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares declined 3.3% to $511.19 in pre-market trading.</li>
<li>Universal Stainless &amp; Alloy Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) fell 2.4% to $39.10 in pre-market trading.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 2.4% to $8.59 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

ARGX

SNOW

USAP

UXIN

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Rumors

Brookfield In Talks With Sovereign Funds To Join Grifols Bid

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares soared 32.91%. The company announced that Lucid Financial Services has added leasing to its range of <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener">financing options in Canada</a>. Fed Chair Powell&#8217;s comments about the economy and interest rate cuts also improved the sentiment.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock rose 32.04% after it reported second-<a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">quarter financial results</a>.</li>
<li>PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) shares escalated 22.67% after the company announced FDA 510(k) clearance of <a href="https://www.benzinga.com//node/40481411" target="_blank" rel="noreferrer noopener">its HYDROS Robotic system</a>.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares were up 20.02%.</li>
<li>Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock upped 19.98% following a report suggesting <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener">the company is exploring a sale</a>.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares jumped 19.50% following a report suggesting that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) is seeking debt financing to acquire the company.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock increased 19.33%.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock escalated 16.60% after it reported better-than-expected second-quarter <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener">results and raised its FY24 EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543876/zoom-video-microstrategy-and-target-were-among-top-11-large-cap-gainers-last-week-aug-18-aug-24-ar" target="_blank" rel="noreferrer noopener">Zoom Video, MicroStrategy And Target Were Among Top 11 Large Cap Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543907/snowflake-jd-com-and-temu-parent-pdd-are-among-top-8-large-cap-losers-last-week-aug-18-aug-24-are-" target="_blank" rel="noreferrer noopener">Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Mid Cap

CRDO

LCID

NUVL

PRCT

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?

GigaGen announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first recombinant...

Grifols doses first patient in Phase 1 trial of GIGA-2339

Grifols slips as Brookfield said to mull $6.9B offer

Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon "without the intervention of the conflicted board members." ...

Grifols says potential Brookfield offer 'significantly undervalues' shares

Grifols slips as board rebuffs Brookfield's $6.8B offer (update)

Key deals this week:  Amcor, ONEOK, Grifols, N-able and more

Grifols drops as Brookfield is said to drop take-private bid

4 stocks to watch on Wednesday: CRWD, GRFS and more

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – Joyy&nbsp;(YY) up 2% Ambarella&nbsp;(AMBA) up...

Morning Movers: Symbotic sinks following delay of 1oK filing

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Dell (DELL) traded down post ear...

Dell and HP forecasts spark selloffs: Morning Buzz

In a notice to the Spanish National Securities Market Commission, Grifols (GRFS) stated: "Grifols announces that its Board of Directors held an ext...

Grifols says 'not feasible' for transaction with Brookfield to move forward

AAPL

AMCR

ARWR

AVAV

BERY

BKNG

ELVA

EXPE

GIFOF

GOGL

GOOG

GOOGL

IREN

MSFT

NABL

QCOM

SEDG

SFTBF

SFTBY

SONY

SYAXF

URBN

XIACF

XIACY

Press Releases

Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

Health Care

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again – Hagens Berman

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Comments

Grifols

ニュース

最新ニュース Grifols (NASDAQ:GRFS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル